Results 111 to 120 of about 4,256 (179)
Sodium-glucose cotransporter 2 inhibitors: mechanisms of cardiorenal protection: A review
Consilium MedicumSodium-glucose cotransporter 2 inhibitors (SGLT-2) are a new class of hypoglycemic drugs that were initially approved for the treatment of type 2 diabetes.
Marina V. Leonova
doaj +1 more source
SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA. [PDF]
Nephrol Dial Transplant, 2023 Mark PB +13 more
europepmc +1 more source
SURPASS‐CVOT and the Emerging Biology of Cardiometabolic Benefit
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8753-8756, October 2026.
Salvatore Corrao +2 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8230-8241, September 2026.ABSTRACT Aim Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are known to reduce serum urate levels, yet their specific impact on gout incidence in the Korean population remains underexplored. We investigated the association between SGLT2i use and incident gout using real‐world data and Mendelian randomisation (MR) analysis. Materials and Methods We
Hong Sang Choi +7 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8407-8417, September 2026.ABSTRACT Aims To evaluate the cardiovascular efficacy and absolute benefit of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) by baseline estimated glomerular filtration rate (eGFR). Materials and Methods PubMed and EMBASE were searched to 29 April 2026 for randomized placebo‐controlled trials of GLP‐1RAs in adults with type 2 diabetes or ...
Masashi Hasebe +3 more
wiley +1 more source
Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease. [PDF]
Kidney Dis (Basel), 2023 Liu W, Yu S.
europepmc +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8460-8468, September 2026.ABSTRACT Aims This study aimed to analyse incident glucose lowering drug (GLD) utilisation in Australia between the period 2014 and 2024. Materials and Methods Australian Pharmaceutical Benefits Scheme (PBS) data (10% PBS dataset) were analysed to assess the proportions of incident monotherapy, dual therapy and triple therapy and the proportion of ...
Peter S. Hamblin +5 more
wiley +1 more source
Journal of Diabetes Investigation, Volume 17, Issue 9, Page 1474-1488, September 2026.Liraglutide combined with Dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice. Diabetic cardiomyopathy (DCM) and endothelial dysfunction were established in mice via HFD and STZ injection. The combination therapy of Liraglutide and Dapagliflozin synergistically improved metabolic parameters and attenuated ...
An‐Jun Tan +5 more
wiley +1 more source
Vicatia thibetica de Boiss Crude Polysaccharide Delay the Aging of the Heart and Kidneys
Food BioengineeringVicatia thibetica de Boiss (V. thibetica) is a medicinal and edible plant traditionally used by the Bai ethnic community in Yunnan, China. Previous studies have reported that extracts derived from its roots have anti‐aging effects, although the active ...
Daoxu Zhang +14 more
doaj +1 more source
Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study. [PDF]
Cureus, 2023 Simões de Carvalho F +4 more
europepmc +1 more source